Krüger K
Rheumatologisches Praxiszentrum, St. Bonifatius Str. 5, 81541, München, Deutschland.
Orthopade. 2018 Nov;47(11):906-911. doi: 10.1007/s00132-018-3650-4.
Rheumatoid arthritis (RA), psoriatic arthritis and axial spondyloarthritis are severe diseases, which without adequate treatment lead to extremely reduced mobility, functional status and quality of life.
The effects of biologics and further new antirheumatic drugs on the burden of disease.
Evaluation of study results and register data dealing with the efficacy and safety of these drugs.
Biologics have been proven to dramatically improve the outcome of all three diseases and contributed to the fact that remission is a realistic target today. In addition, the cardiovascular risk and mortality in RA have been reduced and structural damage is considerably blocked by biologics. Recently Janus kinase (JAK) inhibitors contributed to the treatment possibilities in the same way. Biologics as well as JAK inhibitors offer an excellent safety profile and tolerability with infections being the most important risk.
With the availability of biologics and additional new drugs all three diseases have lost the status of difficult to treat diseases. Their usage according to the guidelines ensures that the burden of disease can been minimalized in most cases. The benefit-risk profile of these drugs has been shown to be excellent.
类风湿关节炎（RA）、银屑病关节炎和轴性脊柱关节炎是严重疾病，若未得到充分治疗，会导致活动能力、功能状态和生活质量极度下降。
生物制剂及其他新型抗风湿药物对疾病负担的影响。
评估有关这些药物疗效和安全性的研究结果及登记数据。
已证实生物制剂可显著改善这三种疾病的预后，使得缓解如今成为一个现实的目标。此外，生物制剂降低了RA的心血管风险和死亡率，并极大地阻止了结构损伤。最近，Janus激酶（JAK）抑制剂也以同样的方式增加了治疗选择。生物制剂和JAK抑制剂均具有良好的安全性和耐受性，感染是最重要的风险。
随着生物制剂和其他新药的出现，这三种疾病都不再属于难治性疾病。按照指南使用这些药物可确保在大多数情况下将疾病负担降至最低。这些药物的效益风险比已被证明是极佳的。
